At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 104 enrolled
Drug / intervention
MK-2206drug
Likely dose
MK-2206 30 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase I Dose Escalation Study of Oral MK-2206 in Patients With Locally Advanced or Metastatic Solid Tumors
In Brief
A Phase 1 clinical trial evaluating MK-2206 for Locally Advanced Tumors and 3 related conditions. Completed, enrolled 104 participants.
Detailed Summary
The primary purpose of this study is to investigate the Dose Limiting Toxicities (DLTs), pharmacokinetics (PK), and pharmacodynamics (PD) of MK-2206 administered orally to participants with advanced solid tumors. The preliminary efficacy of MK-2206 will also be investigated.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsLocally Advanced Tumors, Metastatic Solid Tumors, Cancer, Neoplasms
Countries--
Collaborators--
Timeline
Phase 1CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartApr 2008
First PostedMay 2008
Primary CompletionJul 2011
TodayJul 2026
First PostedMay 1, 2008
Enrollment StartApr 15, 2008
Primary CompletionJul 11, 2011
TodayJul 2, 2026
Enrollment to primary: 3.2 yearsPosted 18.2 years ago
Interventions
MK-2206drug
MK-2206 administered as an oral formulation in rising dose levels on a QOD schedule (30 mg, 60 mg, 75 mg, and 90 mg) or QW schedule (90 mg, 135 mg, 200 mg, 250 mg, and 300 mg) in repeating 4 week cycles, depending upon allocation.